Principles of Cancer Staging. AJCC American Joint Committee on Cancer; [cited 2019 03 15]. Available at: https://cancerstaging.org/references-tools/deskreferences/Documents/Principles%20of%20Cancer%20Staging.pdf.
TNM Classification Help (Manual for Cancer Staging); [cited 2019 10 04]. Available at: http://cancerstaging.blogspot.com/.
Organisation: Atomica Informatics
Email: heather.leslie@atomicainformatics.com
Date originally authored: 2016-08-26
Organisation: Atomica Informatics
Email: heather.leslie@atomicainformatics.com
Date originally authored: 2016-08-26
- Licence: This work is licensed under the Creative Commons Attribution-ShareAlike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-sa/4.0/.
- Custodian Organisation: openEHR Foundation
- References: Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours, 8th Edition. Wiley-Springer; 2016. 272 p. Principles of Cancer Staging. AJCC American Joint Committee on Cancer; [cited 2019 03 15]. Available at: https://cancerstaging.org/references-tools/deskreferences/Documents/Principles%20of%20Cancer%20Staging.pdf. TNM Classification Help (Manual for Cancer Staging); [cited 2019 10 04]. Available at: http://cancerstaging.blogspot.com/.
- Current Contact: Heather Leslie, Atomica Informatics, heather.leslie@atomicainformatics.com
- Original Namespace: org.openehr
- Original Publisher: openEHR Foundation
- Custodian Namespace: org.openehr
- MD5-CAM-1.0.1: 623BAC3524C44A48FA15C2EE2B4243A8
- Build Uid: 924c8d16-72bc-4799-abe9-14b0c4c938b5
- Revision: 1.0.3
Use the value from the TNM variant for each type of cancer. For example: stomach; or small intestine.
Use the value from the TNM variant for each type of cancer. For example: cardia, fundus, corpus, antrum and pylorus (stomach); or duodenum, jejunum or ileum (small intestine).
Coding with a T code appropriate for the tumour type and anatomical site is expected. For example: 'pT1'; or 'pT3'. Represented as 'pT' in the 'TNM assessment'.
Coding with an N code appropriate for the tumour type and anatomical site is expected. For example: 'pNX'; or 'pN2'. Represented as 'pN' in the 'TNM assessment'.
Coding with an M code appropriate for the tumour type and anatomical site is expected. For example: 'pM1'. Represented as 'pM' in the 'TNM assessment'.
Pretreatment histopathological assessment may be determined from a limited biopsy prior to formal resection. Coding with a G code appropriate for the identified tumour type and anatomical site is expected. For example: 'G2'; 'GX'; or 'low grade' for bone and soft tissue sarcoma classification. Represented as 'G' within the 'TNM assessment'.
For example: 'R2 (Macroscopic residual tumour)'. Represented as 'R' within the 'TNM assessment'.
- RX [Presence of residual tumour cannot be assessed.]
- R0 [No residual tumour.]
- R1 [Microscopic residual tumour.]
- R2 [Macroscopic residual tumour.]
For example: 'L0 (No lymphatic invasion)'. Represented as 'L' within the 'TNM assessment'.
- LX [Lymphatic invasion cannot be assessed.]
- L0 [No lymphatic invasion.]
- L1 [Lymphatic invasion.]
For example: 'V1 (Microscopic venous invasion)'. Represented as 'V' within the 'TNM assessment'.
- VX [Venous invasion cannot be assessed.]
- V0 [No venous invasion.]
- V1 [Microscopic venous invasion.]
- V2 [Macroscopic venous invasion.]
For example: 'Pn0 (No perineural invasion)'. Represented as 'Pn' within the 'TNM assessment'.
- PnX [Perineural invasion cannot be assessed.]
- Pn0 [No perineural invasion.]
- Pn1 [Perineural invasion.]
Represented by the suffix, either as '(m)' or the number of primary tumours added to the T code. For example: 'pT2(m)' or 'pT2(4)'. Represented as 'pm' within the 'TNM assessment'.
Choice of:
Count
Boolean
Represented by the prefix 'y' added to the 'TNM assessment'.
Allowed values: {true}
Represented by the prefix 'r' added to the 'TNM assessment'.
Allowed values: {true}
Represented by the prefix 'a' added to the 'TNM assessment'.
Allowed values: {true}
Represented by the prefix 'is' added to the 'TNM assessment'.
Allowed values: {true}
For example: carcinoma in situ is categorised as stage 0; or tumours with distant metastasis are categorised as stage IV.
Represented by the suffix 'sn' added to the 'TNM assessment'.
Allowed values: {true}
Represented by the suffix 'mi' added to the 'TNM assessment'.
Allowed values: {true}
For example 'pN0(i-) No regional lymph node metastasis histologically, negative morphological findings for ITC'; 'pN0(mol+) No regional lymph node metastasis histologically, positive non morphological findings for ITC'; or 'pN0(i+)(sn) No sentinel lymph node metastasis histologically, positive morphological findings for ITC'.
- i- [Negative morphological findings for ITC.]
- i+ [Positive morphological findings for ITC.]
- mol- [Negative non-morphological findings for ITC.]
- mol+ [Positive non-morphological findings for ITC.]
For example: 'pM0(i+)' or 'pM0(mol+)'.
- i- [Negative morphological findings for ITC.]
- i+ [Positive morphological findings for ITC.]
- mol- [Negative non-morphological findings for ITC.]
- mol+ [Positive non-morphological findings for ITC.]
Heidi Aursand, Oslo universitetssykehus, Norway
Silje Ljosland Bakke, Helse Vest IKT AS, Norway (openEHR Editor)
Vegar Dagenborg, OUS, Norway
Kristin Eik, Kreftregisteret, Norway
Hildegard Franke, freshEHR Clinical Informatics Ltd. UK
Sergey Kovalenko, Chelyabinsk Regional Children Hospital, Russia
Siri Laronningen, Kreftregisteret, Norway
Liv Laugen, Oslo universitetssykehus, Norway
Sabine Leh, Haukeland University Hospital, Department of Pathology, Norway
Miha Lenic, Marand, Slovenia
Heather Leslie, Atomica Informatics, Australia (openEHR Editor)
Ian McNicoll, freshEHR Clinical Informatics Ltd. UK
Bjørn Næss, DIPS ASA, Norway
SARA PRETE, Abinsula, Italy
Natalia Strauch, Medizinische Hochschule Hannover, Germany
Norwegian Review Summary, Nasjonal IKT HF, Norway
John Tore Valand, Helse Bergen, Norway (openEHR Editor)
- German: Natalia Strauch, Medizinische Hochschule Hannover, Strauch.Natalia@mh-hannover.de
- Norwegian Bokmål: Vebjørn Arntzen / Sabine Leh, Oslo University Hospital HF / Helse Bergen HF, varntzen@ous-hf.no